Theravance Biopharma (TBPH) Misses Q1 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Theravance Biopharma, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
May 5, 2022 4:05 PM EDTImplied 35% share of YUPELRI® (revefenacin) net sales1: $15.3M Q1 2022 up 19% from Q1 2021TRELEGY Q1 2022 global net sales: $454M, up 33% from Q1 20212Results from a Phase 3 study of ampreloxetine showed a benefit in study patients with multiple system atrophy (MSA) Restructuring process completed in Q1 2022
DUBLIN, May 5, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the first quarter of 2022.
... More